The FDA has approved Ryzodeg 70/30 (insulin degludec/insulin aspart injection) from Novo Nordisk, to improve blood sugar (glucose) control in...
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee has unanimously recommended that a cardiovascular outcomes trial should be conducted regarding...
When treated with once-daily Ryzodeg, from Novo Nordisk, people with type 2 diabetes achieved similar blood sugar control with half...
On 18 October 2012, the CHMP adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal...
On 18 October 2012 the CHMP adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal...
Novo Nordisk has announced that the European Commission on 21 January 2013, has granted marketing authorisations for Tresiba (insulin degludec) and...
Data presented at the World Diabetes Congress of the International Diabetes Federation (IDF) show that adults with Type 2 Diabetes...
New analyses demonstrate that Ryzodeg (insulin degludec/insulin aspart), from Novo Nordisk, achieved successful glycaemic control with significantly lower rates of...
Data presented at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD) show that Ryzodeg...
Novo Nordisk have announced that the FDA has accepted for review the Class II Resubmissions for Tresiba (insulin degludec) and...